Adaptive Biotechnologies Corp — Director's Dealing 2025

Mar 7, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptive Biotechnologies Corp (ADPT)
CIK: 0001478320
Period of Report: 2025-03-04

Reporting Person: ROBINS CHAD M (Director, CEO and Chairman)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-03-04	Common Stock	A	355000	—	Acquired	2931701	Direct
2025-03-05	Common Stock	S	81206	$6.98	Disposed	2850495	Direct
2025-03-05	Common Stock	S	36145	$6.99	Disposed	2814350	Direct
2025-03-05	Common Stock	A	247117	—	Acquired	3061467	Direct
2025-03-06	Common Stock	S	102218	$7.64	Disposed	2959249	Direct

Footnotes

F1: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F2: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. The performance share units were granted on March 4, 2022, with respect to the three-year period ending on March 4, 2025. The issuer certified the achievement of the performance goals on March 5, 2025. The performance share units vested on March 5, 2025.

F3: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance share units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.